Algernon Health CEO Christopher Moreau joined Steve Darling from Proactive to announce that the company has entered into a significant strategic business and investment agreement with American Molecular Imaging, one of the premier radiology reading services providers in the United States. The partnership is designed to ensure that every patient visiting Algernon’s planned U.S. brain-focused neuroimaging clinics receives top-tier PET scan interpretations delivered with unmatched accuracy and turnaround times. Moreau explained that Algernon’s planned clinic network will introduce the first dedicated, brain-optimized PET neuroimaging centers in the United States, facilities engineered to detect early signs of Alzheimer’s disease with exceptional precision. In addition to Alzheimer’s diagnostics, the clinics will offer advanced PET imaging for a broad range of neurological conditions, including other dementias, epilepsy, neuro-oncology indications, and movement disorders. Under the terms of the new partnership, AMI will become the exclusive radiology reading services provider for all of Algernon’s future neuroimaging clinics. To further strengthen the collaboration, AMI will make a US$250,000 strategic investment in Algernon’s recently announced private placement, and an additional US$250,000 investment into Algernon USA LLC—the company’s newly formed subsidiary tasked with overseeing all U.S. neuroimaging operations. Algernon USA LLC is leading efforts to open the first clinic, currently targeted for early 2026. Moreau also highlighted another key milestone: Algernon has finalized an equipment order, financing package, and consulting agreement with Catalyst MedTech, a recognized leader in medical imaging technologies. This non-dilutive arrangement, valued at over CAD $4 million, includes four FDA-cleared Oncovision CareMiBrain™ PET scanner systems that will equip the first wave of Algernon’s U.S. clinics. The deal also provides for the acquisition of six additional systems at a reduced cost as the company expands its footprint across the country. #proactiveinvestors #algernonpharmaceuticalsinc #cse #agn #otcqb #agnpf #alzheimerdisease #demetia #AlgernonHealth #AlzheimersDiagnosis #PETScan #BrainImaging #MedicalTechnology #HealthcareInvestment #NeuroImaging #StrategicPartnership #RadiologyInnovation